AlloVir to Participate in the SVB Securities Global Biopharma Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 10:00 a.m. ET. A live webcast and archived replay of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. About All